64 related articles for article (PubMed ID: 10220565)
1. Novel actions of inverse agonists on 5-HT2C receptor systems.
Berg KA; Stout BD; Cropper JD; Maayani S; Clarke WP
Mol Pharmacol; 1999 May; 55(5):863-72. PubMed ID: 10220565
[TBL] [Abstract][Full Text] [Related]
2. Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment.
Hietala J; Kuonnamäki M; Pälvimäki EP; Laakso A; Majasuo H; Syvälahti E
Psychopharmacology (Berl); 2001 Sep; 157(2):180-7. PubMed ID: 11594443
[TBL] [Abstract][Full Text] [Related]
3. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies.
Millan MJ
Therapie; 2005; 60(5):441-60. PubMed ID: 16433010
[TBL] [Abstract][Full Text] [Related]
4. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction.
Chanrion B; Mannoury la Cour C; Gavarini S; Seimandi M; Vincent L; Pujol JF; Bockaert J; Marin P; Millan MJ
Mol Pharmacol; 2008 Mar; 73(3):748-57. PubMed ID: 18083778
[TBL] [Abstract][Full Text] [Related]
5. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.
De Deurwaerdère P; Navailles S; Berg KA; Clarke WP; Spampinato U
J Neurosci; 2004 Mar; 24(13):3235-41. PubMed ID: 15056702
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Biological Evaluation of Disubstituted Pyrimidines as Selective 5-HT
Kim J; Kim YJ; Londhe AM; Pae AN; Choo H; Kim HJ; Min SJ
Molecules; 2019 Sep; 24(18):. PubMed ID: 31491978
[TBL] [Abstract][Full Text] [Related]
7. Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity.
Berg KA; Clarke WP
Int J Neuropsychopharmacol; 2018 Oct; 21(10):962-977. PubMed ID: 30085126
[TBL] [Abstract][Full Text] [Related]
8. A short history of the 5-HT
Palacios JM; Pazos A; Hoyer D
Psychopharmacology (Berl); 2017 May; 234(9-10):1395-1418. PubMed ID: 28265714
[TBL] [Abstract][Full Text] [Related]
9. Constitutive Desensitization of Opioid Receptors in Peripheral Sensory Neurons.
Sullivan LC; Chavera TS; Jamshidi RJ; Berg KA; Clarke WP
J Pharmacol Exp Ther; 2016 Dec; 359(3):411-419. PubMed ID: 27660244
[TBL] [Abstract][Full Text] [Related]
10. Similarities between the Binding Sites of SB-206553 at Serotonin Type 2 and Alpha7 Acetylcholine Nicotinic Receptors: Rationale for Its Polypharmacological Profile.
Möller-Acuña P; Contreras-Riquelme JS; Rojas-Fuentes C; Nuñez-Vivanco G; Alzate-Morales J; Iturriaga-Vásquez P; Arias HR; Reyes-Parada M
PLoS One; 2015; 10(8):e0134444. PubMed ID: 26244344
[TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotics and inverse agonism at 5-HT2 receptors.
Sullivan LC; Clarke WP; Berg KA
Curr Pharm Des; 2015; 21(26):3732-8. PubMed ID: 26044975
[TBL] [Abstract][Full Text] [Related]
12. Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex.
Nocjar C; Alex KD; Sonneborn A; Abbas AI; Roth BL; Pehek EA
Neuroscience; 2015 Jun; 297():22-37. PubMed ID: 25818050
[TBL] [Abstract][Full Text] [Related]
13. Nucleus accumbens shell excitability is decreased by methamphetamine self-administration and increased by 5-HT2C receptor inverse agonism and agonism.
Graves SM; Clark MJ; Traynor JR; Hu XT; Napier TC
Neuropharmacology; 2015 Feb; 89():113-21. PubMed ID: 25229719
[TBL] [Abstract][Full Text] [Related]
14. Signalling profile differences: paliperidone versus risperidone.
Clarke WP; Chavera TA; Silva M; Sullivan LC; Berg KA
Br J Pharmacol; 2013 Oct; 170(3):532-45. PubMed ID: 23826915
[TBL] [Abstract][Full Text] [Related]
15. Quantitative changes in intracellular calcium and extracellular-regulated kinase activation measured in parallel in CHO cells stably expressing serotonin (5-HT) 5-HT2A or 5-HT2C receptors.
Seitz PK; Bremer NM; McGinnis AG; Cunningham KA; Watson CS
BMC Neurosci; 2012 Mar; 13():25. PubMed ID: 22397586
[TBL] [Abstract][Full Text] [Related]
16. Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation.
Canal CE; Cordova-Sintjago TC; Villa NY; Fang LJ; Booth RG
Eur J Pharmacol; 2011 Dec; 673(1-3):1-12. PubMed ID: 22020288
[TBL] [Abstract][Full Text] [Related]
17. Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity.
Murray KC; Stephens MJ; Ballou EW; Heckman CJ; Bennett DJ
J Neurophysiol; 2011 Feb; 105(2):731-48. PubMed ID: 20980537
[TBL] [Abstract][Full Text] [Related]
18. Acquisition session length modulates consolidation effects produced by 5-HT2C ligands in a mouse autoshaping-operant procedure.
Walker EA; Foley JJ
Behav Pharmacol; 2010 Mar; 21(2):83-9. PubMed ID: 20177374
[TBL] [Abstract][Full Text] [Related]
19. Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), ketanserin, and (R)-(+)-{alpha}-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907) in rats.
Li JX; Unzeitig A; Javors MA; Rice KC; Koek W; France CP
J Pharmacol Exp Ther; 2009 Nov; 331(2):671-9. PubMed ID: 19687292
[TBL] [Abstract][Full Text] [Related]
20. RNA editing of the serotonin 2C receptor and expression of Galpha(q) protein: genetic mouse models do not support a role for regulation or compensation.
Canal CE; Mahautmr KC; Cao C; Sanders-Bush E; Airey DC
J Neurochem; 2009 Mar; 108(5):1136-42. PubMed ID: 19154337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
